Universal DX Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test To Patients And Providers In The United States
Portfolio Pulse from Benzinga Newsdesk
Universal DX (UDX) has announced a strategic collaboration with Quest Diagnostics (NYSE:DGX) to bring an advanced colorectal cancer screening blood test, Signal-C®, to the U.S. market, pending FDA approval. The collaboration includes a 15,000-patient study for FDA premarket approval, with Quest providing clinical laboratory services. UDX also closed its series B financing round, raising approximately $70 million, with Quest as an investor. Signal-C® has shown high sensitivity and specificity in preliminary studies and aims to improve screening accessibility and convenience.
November 20, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics (DGX) enters a strategic partnership with UDX to offer an advanced colorectal cancer screening test, Signal-C®, subject to FDA approval. Quest will perform clinical laboratory services and has invested in UDX's series B financing. The collaboration could enhance Quest's service offerings and potentially increase revenue streams.
The partnership with UDX positions Quest Diagnostics at the forefront of colorectal cancer screening, a significant market given the eligibility of over 110 million Americans. The investment in UDX's series B financing and the potential exclusive rights to provide the test post-FDA approval suggest a strong commitment to the product and an expectation of a positive impact on Quest's business. The preliminary study results showing high sensitivity and specificity of Signal-C® indicate a competitive edge in the market, which could lead to increased demand for Quest's services.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90